New board member of CLS buys shares in the company and the CEO and EVP Operations increase their shareholdings

Lund, Sweden – Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announces that the Company's new Board member Peter Mantas, the CEO, Dan J. Mogren, and EVP Operations, Jimmy Johansson, have purchased a total of 22,000 Class B shares in CLS.

Peter Mantas acquired 10,000 shares bringing his total holding to 10,000 Class B shares on Wednesday, November 6th.

Dan J. Mogren completed the purchase of 8,000 shares on November 5th. After the transactions, Dan J. Mogren's total holding amounts to 30,939 Class B shares plus 632 Class B shares via Medinovus AB.

Jimmy Johansson acquired 4,000 shares through his company Medtech Öresund AB on Thursday, October 31st. After the transactions, Jimmy Johansson's total holding amounts to 429 Class B shares plus 25,608 Class B shares via Medtech Öresund AB.

The shares were purchased in ongoing trading on Nasdaq First North Growth Market Stockholm.

For more information, please contact:

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0) 70-590 11 40

E-post: [email protected]

About CLS

Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG®|Thermal Therapy System and ClearPoint Prism Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold through partners for image-guided laser ablation and are used in studies for treatment with imILT®, the company's interstitial laser thermotherapy for immune stimulating ablation with potential abscopal treatment effect. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: www.clinicallaser.se